Radhika Gharpure1,2, John Bliton1, Alexandra Goodman1, Ibne Karim M Ali1, Jonathan Yoder1, Jennifer R Cope1. 1. Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Epidemic Intelligence Service Program, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: Primary amebic meningoencephalitis (PAM) is a rapidly progressive and often fatal condition caused by the free-living ameba Naegleria fowleri. To estimate the global occurrence, characterize the epidemiology, and describe the clinical features of PAM, we report a series of PAM cases published in the international literature and reported to the Centers for Disease Control and Prevention (CDC). METHODS: We performed a literature search of PAM case reports published through 2018. Additionally, we included cases reported through the CDC's Free-Living Ameba surveillance or diagnosed via CDC's Free-Living and Intestinal Amebas Laboratory. Cases were classified as confirmed, probable, or suspect on the basis of confirmatory testing, presentation, exposure, and disease course. RESULTS: A total of 381 PAM cases were identified. Seven reported survivors were classified as confirmed. The most commonly reported exposure associated with PAM was swimming/diving, and the most common class of water source was lakes/ponds/reservoirs. Patients were predominantly male (75%), with a median age of 14 years. Confirmed and probable cases were similar in their survival, course of illness, and cerebrospinal fluid (CSF) findings. CONCLUSIONS: PAM is a rare but deadly disease with worldwide occurrence. Improved clinician awareness, resulting in earlier diagnosis and treatment, may contribute to increased survival among PAM patients. The case definition of probable used in this study appears to capture cases of PAM, as evidenced by similarities in outcomes, clinical course, and CSF profile to confirmed cases. In the absence of confirmatory testing, clinicians could use this case definition to identify cases of PAM. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Primary amebic meningoencephalitis (PAM) is a rapidly progressive and often fatal condition caused by the free-living ameba Naegleria fowleri. To estimate the global occurrence, characterize the epidemiology, and describe the clinical features of PAM, we report a series of PAM cases published in the international literature and reported to the Centers for Disease Control and Prevention (CDC). METHODS: We performed a literature search of PAM case reports published through 2018. Additionally, we included cases reported through the CDC's Free-Living Ameba surveillance or diagnosed via CDC's Free-Living and Intestinal Amebas Laboratory. Cases were classified as confirmed, probable, or suspect on the basis of confirmatory testing, presentation, exposure, and disease course. RESULTS: A total of 381 PAM cases were identified. Seven reported survivors were classified as confirmed. The most commonly reported exposure associated with PAM was swimming/diving, and the most common class of water source was lakes/ponds/reservoirs. Patients were predominantly male (75%), with a median age of 14 years. Confirmed and probable cases were similar in their survival, course of illness, and cerebrospinal fluid (CSF) findings. CONCLUSIONS: PAM is a rare but deadly disease with worldwide occurrence. Improved clinician awareness, resulting in earlier diagnosis and treatment, may contribute to increased survival among PAM patients. The case definition of probable used in this study appears to capture cases of PAM, as evidenced by similarities in outcomes, clinical course, and CSF profile to confirmed cases. In the absence of confirmatory testing, clinicians could use this case definition to identify cases of PAM. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Jennifer R Cope; Dennis A Conrad; Naiomi Cohen; Manuel Cotilla; Alexandre DaSilva; Jonathan Jackson; Govinda S Visvesvara Journal: Clin Infect Dis Date: 2015-12-17 Impact factor: 9.079
Authors: Linda G Capewell; Aaron M Harris; Jonathan S Yoder; Jennifer R Cope; Brittany A Eddy; Sharon L Roy; Govinda S Visvesvara; LeAnne M Fox; Michael J Beach Journal: J Pediatric Infect Dis Soc Date: 2014-10-23 Impact factor: 3.164
Authors: Glenn R Harris; Ellora N Karmarkar; Rebecca Quenelle; Lyndsey Chaille; Jai Madhok; Vivian Tien; Jyoti Gupta; Seema Jain; Maria Liu; Shantanu Roy; Supriya Narasimhan; Akiko Kimura; Jennifer R Cope; Ibne Karim M Ali Journal: Open Forum Infect Dis Date: 2021-07-27 Impact factor: 3.835
Authors: Tatiana Y Hargrove; Zdzislaw Wawrzak; Girish Rachakonda; W David Nes; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva Journal: J Med Chem Date: 2021-11-29 Impact factor: 7.446
Authors: Radhika Gharpure; Michelle Gleason; Zainab Salah; Anna J Blackstock; David Hess-Homeier; Jonathan S Yoder; Ibne Karim M Ali; Sarah A Collier; Jennifer R Cope Journal: Emerg Infect Dis Date: 2021-01 Impact factor: 6.883
Authors: Emily K Herman; Alex Greninger; Mark van der Giezen; Michael L Ginger; Inmaculada Ramirez-Macias; Haylea C Miller; Matthew J Morgan; Anastasios D Tsaousis; Katrina Velle; Romana Vargová; Kristína Záhonová; Sebastian Rodrigo Najle; Georgina MacIntyre; Norbert Muller; Mattias Wittwer; Denise C Zysset-Burri; Marek Eliáš; Claudio H Slamovits; Matthew T Weirauch; Lillian Fritz-Laylin; Francine Marciano-Cabral; Geoffrey J Puzon; Tom Walsh; Charles Chiu; Joel B Dacks Journal: BMC Biol Date: 2021-07-22 Impact factor: 7.431